Understanding the U.K.’s International Recognition Procedure
The introduction of the IRP has brought opportunities for faster market access for manufacturers by enabling the MHRA to conduct more targeted assessments by taking into account the expertise and decision-making of trusted regulatory partners.
The IRP also allows the MHRA to perform product lifecycle activities utilized for post-approval submissions, including line extensions, variations (Type IB and Type II) and renewals for a medicinal product with an existing Marketing Authorisation (MA) granted by one of the MHRA’s acceptable reference regulators (RRs), which include:
| Country or jurisdiction | Regulatory authority |
|---|---|
| Australia | Therapeutic Goods Administration |
| Canada | Health Canada |
| Switzerland | Swissmedic |
| Singapore | Health Sciences Authority |
| Japan | Pharmaceuticals and Medical Devices Agency |
| United States | Food and Drug Administration |
| European Union/European Economic Area | European Medicines Agency and Member State Competent Authorities of the EU, Norway, Iceland and Liechtenstein. (This includes approvals through the centralized, MRP/DCP and individual member state national routes.) |
The IRP may also be used for Access Consortium approvals that did not include the MHRA as part of the work-sharing procedure.1
IRP process
New IRP marketing authorization application (MAA)
A new MA may be achieved via one of two possible recognition pathways:
- Recognition A is applicable if the reference regulator MA has been granted within the previous 2 years1 (60-day procedure, no clock stop).
- Recognition B is applicable if the reference regulator MA has been granted within the previous 10 years and fulfills at least 1 of the 24 listed criteria (110-day procedure with no more than 1 clock stop). If there are outstanding Major Objections at Day 110, formal advice on approvability will be sought from the CHM, and the timetable will revert to the national 210-day timetable.1
Update: As of July 13, 2026, the MHRA has shortened the Recognition B window. The reference regulator’s approval must now have been granted within the previous 5 years, rather than 10 years. Recognition A is unchanged at 2 years. A transition phase allowed applicants to use the previous process until Aug. 31, 2026.2
Post-authorization IRP applications: Variations and renewals
The IRP can be used during the lifecycle of products that have been initially authorized or subsequently varied via standalone national, MRDCRP or ECDRP routes. Conversely, where a product has been authorized via the IRP, it is acceptable to submit standalone national post-authorization procedures, including variations.1
Full details of the IRP submission process and requirements are provided on the MHRA website:
Who can apply?
In some situations, it may be possible to accept applications from third parties if the applicant can demonstrate and provide written assurance that all the legal obligations can be met at submission, during the assessment process and throughout the life of the MA.1
Key advantages of using the IRP
Expansion of international collaborations
Fast market access
Expedited approval with review times of 60 days (Route A) and 110 days (Route B) is significantly shorter than the MHRA national route for MAA,1 which has a 210-day timetable. This will allow quicker market access for medicines authorized outside of the EU and reduce assessment pressure and time burden on the MHRA.
MHRA support
The IRP has been operational since January 1, 2024. In December 2024, a total of 265 IRP submissions (Type IB: 190; Type II: 75) were approved, with 95% to 97% granted within the statutory timeframe.4
Other considerations
Eligibility constraints
The IRP is only applicable to:
- Chemical and biological new active substances and known active substances
- Generic applications
- Hybrid applications
- Biosimilar applications
- New fixed combination product applications
It is not applicable to:
- Bibliographic applications
- Traditional herbal registrations
- Homeopathic registrations
Ansvarsfraskrivelse:
Informasjonen i denne artikkelen er ment å informere leserne om et emne relatert til Cencoras evner og er ikke juridisk eller kjøpsrådgivning. Cencora, Inc. oppfordrer leserne til å gjennomgå de siterte referansene i denne artikkelen og bruke sin egen kunnskap og erfaring når de tar beslutninger.
Related solutions
References
1. Medicines and Healthcare products Regulatory Agency. "International Recognition Procedure." GOV.UK, Jan. 29, 2024.
2. Medicines and Healthcare products Regulatory Agency. "International Recognition Procedure." GOV.UK, updated Oct. 9, 2026.
3. Medicines and Healthcare products Regulatory Agency. "Pre-Submission Advice & Support for Innovative Medicines." GOV.UK, Aug. 13, 2024.
4. Medicines and Healthcare products Regulatory Agency. "Assessment of New Marketing Authorisation Applications and Variations." December 2024.
